MER-XMT-1660-1

A PHASE 1B, FIRST IN HUMAN, DOSE ESCALATION AND EXPANSION, MULTICENTER STUDY OF XMT- 1660 IN PARTICIPANTS WITH SOLID TUMORS

Condition: Solid Tumors- HR+/HER2- BC, TNBC, Endometrial Cancer, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Last Updated: 3 Jun 2022 | Status: open

View Full Study